These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 2274383)

  • 1. [Consensus and controversy in adjuvant treatment indications in breast cancers].
    Rouëssé J
    Pathol Biol (Paris); 1990 Oct; 38(8):846-7. PubMed ID: 2274383
    [No Abstract]   [Full Text] [Related]  

  • 2. [Adjuvant therapy of breast cancer].
    Semiglazov VF; Abzumanov AS; Bozhok AA; Ivanov VG; Ivanova OA; Barash NIu; Topuzov EE; Seleznev IK; Migmanova NSh; Popova RT; Nurgaziev KSh
    Khirurgiia (Mosk); 2001; (5):52-60. PubMed ID: 11505673
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumor angiogenesis in women with node-positive breast cancer.
    Folkman J
    Cancer J Sci Am; 1995; 1(2):106-8. PubMed ID: 9166461
    [No Abstract]   [Full Text] [Related]  

  • 4. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract]   [Full Text] [Related]  

  • 5. Medical management of breast cancer.
    Crown JP; Fennelly JJ
    Ir Med J; 1993; 86(5):143-5. PubMed ID: 8225913
    [No Abstract]   [Full Text] [Related]  

  • 6. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Breast carcinoma in accessory gland: a case report].
    Sivelli R; Del Rio P; Arcuri MF; Corcione L
    G Chir; 2002 May; 23(5):179-80. PubMed ID: 12228967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
    J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet!
    Samur M; Bozcuk HS
    J Clin Oncol; 2003 Jun; 21(12):2444; author reply 2445-7. PubMed ID: 12805349
    [No Abstract]   [Full Text] [Related]  

  • 12. [Adjuvant chemo-hormonal therapy of breast cancer. New results on mortality].
    Kaufmann M; Kubli F; Caffier H; Jonat W; Maass H
    Dtsch Med Wochenschr; 1985 Jun; 110(25):1009-10. PubMed ID: 3839181
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant therapy for breast cancer.
    Melnychuk D; Panasci LC
    N Engl J Med; 1994 Sep; 331(11):741-2; author reply 744-5. PubMed ID: 8058084
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of anti-oestrogen Zitazonium (tamoxifen) as adjuvant to cytostatic treatment in metastatic breast cancer.
    Palka I; Jávor J
    Ther Hung; 1986; 34(4):217-23. PubMed ID: 3449976
    [No Abstract]   [Full Text] [Related]  

  • 15. [Esthetic results of the conservative treatment in breast carcinoma].
    Moro G
    Radiol Med; 1995 Oct; 90(4):481-5. PubMed ID: 8552828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prospective randomized trial on the efficacy of adjuvant endocrine therapy for ER-positive breast cancer patients after radical mastectomy].
    Jiang Z; Song S; Liu X
    Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):420-2. PubMed ID: 11810777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy for breast cancer.
    Flippin TA; Langston HD; Prather JL; Scott DI
    J Ark Med Soc; 1987 May; 83(12):483-4. PubMed ID: 2956244
    [No Abstract]   [Full Text] [Related]  

  • 18. [Adjuvant treatment of breast carcinoma].
    Bruning PF; Bartelink H; van Dongen JA; Peterse JL
    Ned Tijdschr Geneeskd; 1993 Nov; 137(46):2364-70. PubMed ID: 8264820
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
    Rudas M; Lehnert M; Huynh A; Jakesz R; Singer C; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Grill R; Stierer M; Gnant MF; Filipits M;
    Clin Cancer Res; 2008 Mar; 14(6):1767-74. PubMed ID: 18347178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen). CMEA Cooperative Treatment Group.
    Neoplasma; 1985; 32(3):381-7. PubMed ID: 2862594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.